CytoDyn’s Leronlimab Decreased Mortality at 14 Days by 82% With Statistically Significant P-Value of 0.0233 Amongst Critically Ill COVID-19 Patients
Length in hospital stay decreased by 5.5 days in the critically ill population (N=62, p=.005).
- Length in hospital stay decreased by 5.5 days in the critically ill population (N=62, p=.005).
- The FDA has granted a FastTrack designation to CytoDyn for two potential indications of leronlimab for critical illnesses.
- The first indication is combination therapy with HAART for HIV-infected patients, and the second is for metastatic triple-negative breast cancer.
- CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab combined with standard antiretroviral therapies in HIV-infected treatment-experienced patients.